pravastatin has been researched along with Dyslipidemia in 60 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 17 (28.33) | 29.6817 |
| 2010's | 40 (66.67) | 24.3611 |
| 2020's | 3 (5.00) | 2.80 |
| Authors | Studies |
|---|---|
| Choi, JK; Jeon, TH; Kang, SY; Kim, DH; Kim, K; Kim, YS; Shin, HY; Sunwoo, S; Yoon, JL; Yum, KS | 1 |
| Alkaabi, M; Amoodi, AA; Baraka, MA; Don, J; Elnour, AA; Farah, FH; Mazrouei, NA; Ramadan, A; Sadeq, A; Sam, KG | 1 |
| Liu, L; Su, R; Wen, T; Xiao, Z; Xie, Y; Xu, J; Zhang, M; Zhu, L | 1 |
| Aberg, JA; Campbell, SE; Kryzhanovski, VA; Sponseller, CA; Thompson, MA; Ward, DJ | 1 |
| Bae, J; Kryzhanovski, VA; LeNarz, LA; Sponseller, CA; Zhao, Z; Zhu, Y | 1 |
| Camacho, X; Carter, AA; Gomes, T; Juurlink, DN; Mamdani, MM; Shah, BR | 1 |
| Al-Hamaq, AO; Barakat, L; Bener, A; Dogan, M | 1 |
| Campbell, SE; Davidson, MH; Kryzhanovski, VA; Morgan, RE; Sponseller, CA | 1 |
| Díaz Rodríguez, Á | 1 |
| Flores-Le Roux, JA; Pedro-Botet, J | 1 |
| Mantilla, T | 1 |
| Núñez-Cortés, JM | 1 |
| Pintó, X | 1 |
| Annoni, F; Caputo, S; Cremona, AM; Grandi, AM; Grossi, P; Guasti, L; Marchesi, C; Maresca, AM; Nicolini, E; Rizzi, L | 1 |
| González, DF | 1 |
| Seo, HS | 1 |
| Baek, SH; Cho, HJ; Jeon, HK; Kang, SM; Kim, HY; Lee, HY; Shin, JH | 1 |
| Medvedev, IN; Skoriatina, IA | 1 |
| Aparicio, B; Bueno, MJ; Castaño, M; Centeno, JE; Díez, R; García, B; García-Criado, FJ; González-Santos, JM; López, J; Rodríguez, JM; Sagredo, V | 1 |
| Gouya, G; Herkner, H; Mesgarpour, B; Reichardt, B; Wolzt, M | 1 |
| Deedwania, PC; Fayyad, RS; Laskey, RE; Stone, PH; Wilson, DJ | 1 |
| D'Agostino, RB; Jones, SR; Joshi, PH; Martin, SS; Massaro, JM; Miller, PE; Sponseller, CA; Toth, PP | 1 |
| Roever, L | 1 |
| Baila-Rueda, L; Cenarro, A; Civeira, F | 1 |
| Abdel-Rahman, SZ; El-Mesallamy, HO; Hamdy, NM; Mostafa, AM | 1 |
| D'Agostino, RB; Jones, SR; Joshi, PH; Kulkarni, KR; Martin, SS; Massaro, JM; Miller, PE; Sponseller, C; Toth, PP | 1 |
| Nambi, V; Polsani, VR; Virani, SS | 1 |
| Arima, S; Kai, T; Kanamasa, K; Nakabou, M; Taniyama, Y | 1 |
| Castro-Beiras, A; Crespo-Leiro, MG; Flores, X; Franco, R; Grille, Z; Marzoa, R; Mosquera, V; Naya, C; Paniagua, MJ; Rodriguez, JA | 1 |
| Kushiro, T; Mizuno, K; Nakamura, H; Nakaya, N; Ohashi, Y; Tajima, N; Teramoto, T; Uchiyama, S | 1 |
| Aliabadi, AZ; Dunkler, D; Grimm, M; Grömmer, M; Mahr, S; Wolner, E; Zimpfer, D; Zuckermann, AO | 1 |
| Cope, D; Iskander, E; Mikhail, N | 1 |
| Koh, KK | 1 |
| Aslangul, E; Assoumou, L; Bittar, R; Boccara, F; Bonnefont-Rousselot, D; Costagliola, D; Fiévet, MH; Giral, P; Kalmykova, O; Melchior, JC; Peytavin, G; Valantin, MA | 1 |
| Bergin, C; Moriarty, M; Nolan, DP; O'Connor, C; O'Connor, MB; O'Leary, A | 1 |
| Hayashi, J; Hayashi, S; Maeda, S; Ohnishi, H; Sawayama, Y | 1 |
| Aoki, K; Harada, Y; Kamiyama, H; Kaneshiro, M; Kuwabara, T; Natsumeda, Y; Nezu, U; Ohshige, K; Seki, Y; Shigematsu, E; Terauchi, Y; Tomura, S; Tsunoda, S; Yamakawa, T; Yoshimura, H | 1 |
| Wilke, RA | 1 |
| Betteridge, J | 1 |
| Aslangul, E; Assoumou, LK; Bastard, JP; Capeau, J; Costagliola, D; Fellahi, S | 1 |
| Kakinoki, S; Kushiro, T; Mizuno, K; Nakamura, H; Nakaya, N; Ohashi, Y; Teramoto, T; Yokoyama, S | 1 |
| Al-Khateeb, A; Ibrahim, S; Imran, K; Mohamed, MS; Yusof, Z; Zilfalill, BA | 1 |
| Aberg, JA; Evans, SE; Fichtenbaum, CJ | 1 |
| Ballantyne, CM; Burgess, T; Kallend, D; Miller, M; Niesor, EJ; Stein, EA | 1 |
| Budinski, D; Gosho, M; Hounslow, N; Stender, S | 1 |
| Fukui, K; Hibi, K; Kunishima, T; Michishita, I; Nozue, T; Onishi, Y; Terashima, M; Tohyama, S; Umezawa, S; Yamamoto, S | 1 |
| Aslangul, E; Assoumou, L; Bittar, R; Bonnefont-Rousselot, D; Cherfils, C; Costagliola, D; Federspiel, MC; Giral, P; Kalmykova, O; Valantin, MA | 1 |
| Daida, H; Kitagawa, Y; Teramoto, T | 1 |
| Biro, S; Ikeda, Y; Kono, S; Otonari, T; Sasaki, J; Uchida, Y | 1 |
| Ayaori, M; Ikewaki, K; Ishikawa, T; Mizuno, K; Nakamura, H; Nishiwaki, M; Ohashi, Y; Ohsuzu, F | 1 |
| Matsuo, M; Sawada, M; Seki, J | 1 |
| Davidson, M | 1 |
| Balice, M; Chironi, G; Del-Pino, M; Gariepy, J; Levenson, J; Simon, A | 1 |
| Hayashi, J; Kikuchi, K; Maeda, N; Okada, K; Sawayama, Y; Tatsukawa, M | 1 |
| Deray, G; Isnard-Bagnis, C; Karie, S; Launay-Vacher, V | 1 |
| Vos, E | 1 |
| Alsheikh-Ali, AA; Karas, RH | 1 |
| Broncel, M; Chojnowska-Jezierska, J; Koter-Michalak, M | 1 |
| Doncheva, NI; Nikolov, KV; Vassileva, DP | 1 |
| Farmer, JA; Jones, PH | 1 |
7 review(s) available for pravastatin and Dyslipidemia
| Article | Year |
|---|---|
A Systematic Review of Randomized Clinical Trials on the Efficacy and Safety of Pitavastatin.
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Dyslipidemias; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Metabolic Syndrome; Pravastatin; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin | 2023 |
Non-cholesterol Sterols in the Diagnosis and Treatment of Dyslipidemias: A Review.
Topics: Bile Acids and Salts; Cholesterol; Dyslipidemias; Ezetimibe; Humans; Membrane Proteins; Membrane Transport Proteins; Oxysterols; Phytosterols; Pravastatin; Sterols | 2016 |
High-density lipoprotein (HDL) cholesterol: leveraging practice-based biobank cohorts to characterize clinical and genetic predictors of treatment outcome.
Topics: Apolipoprotein A-I; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Databases, Nucleic Acid; Dose-Response Relationship, Drug; Dyslipidemias; Electronic Health Records; Genetic Association Studies; Genetic Markers; Heptanoic Acids; Humans; Obesity; Pravastatin; Pyrroles; Risk Assessment; Simvastatin; Treatment Outcome | 2011 |
Pitavastatin - results from phase III & IV.
Topics: Atorvastatin; Clinical Trials, Phase III as Topic; Clinical Trials, Phase IV as Topic; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Pyrroles; Quinolines; Simvastatin | 2010 |
Considerations in the treatment of dyslipidemia associated with chronic kidney failure and renal transplantation.
Topics: Atorvastatin; Comorbidity; Dyslipidemias; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Kidney Failure, Chronic; Kidney Transplantation; Lovastatin; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2005 |
[Statins in patients with kidney failure: efficacy, tolerance, and prescription guidelines in patients with chronic kidney disease and renal transplant].
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Dyslipidemias; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Graft Rejection; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Kidney Failure, Chronic; Liver Transplantation; Middle Aged; Pravastatin; Primary Prevention; Prospective Studies; Proteinuria; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Renal Dialysis; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Time Factors | 2006 |
Adjunctive interventions in myocardial infarction: the role of statin therapy.
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atorvastatin; Coronary Artery Disease; Coronary Circulation; Coronary Occlusion; Dyslipidemias; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Plasminogen Activator Inhibitor 1; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic | 2008 |
21 trial(s) available for pravastatin and Dyslipidemia
| Article | Year |
|---|---|
Effects of Xuezhikang versus Pravastatin on Triglyceride Level in Patients with T2DM and Dyslipidemia: Study Protocol for a Multicenter Randomized Controlled Trial.
Topics: Atherosclerosis; Diabetes Mellitus, Type 2; Dyslipidemias; Humans; Lipids; Multicenter Studies as Topic; Pravastatin; Randomized Controlled Trials as Topic; Triglycerides | 2023 |
Pitavastatin versus pravastatin in adults with HIV-1 infection and dyslipidaemia (INTREPID): 12 week and 52 week results of a phase 4, multicentre, randomised, double-blind, superiority trial.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Anticholesteremic Agents; Cholesterol, LDL; Double-Blind Method; Dyslipidemias; Female; HIV Infections; Humans; Male; Middle Aged; Placebos; Pravastatin; Puerto Rico; Quinolines; Treatment Outcome; United States; Young Adult | 2017 |
Comparison of the lipid-lowering effects of pitavastatin 4 mg versus pravastatin 40 mg in adults with primary hyperlipidemia or mixed (combined) dyslipidemia: a Phase IV, prospective, US, multicenter, randomized, double-blind, superiority trial.
Topics: Aged; Apolipoproteins B; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Dyslipidemias; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Pravastatin; Prospective Studies; Quinolines; Triglycerides | 2014 |
Dyslipidemia in HIV-positive patients: a randomized, controlled, prospective study on ezetimibe+fenofibrate versus pravastatin monotherapy.
Topics: Adult; Anticholesteremic Agents; Azetidines; Drug-Related Side Effects and Adverse Reactions; Dyslipidemias; Ezetimibe; Female; Fenofibrate; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Pravastatin; Prospective Studies; Treatment Outcome | 2014 |
Effects of intensive versus mild lipid lowering by statins in patients with ischemic congestive heart failure: Korean Pitavastatin Heart Failure (SAPHIRE) study.
Topics: Aged; Biomarkers; Cholesterol, LDL; Down-Regulation; Dyslipidemias; Exercise Tolerance; Female; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Ischemia; Pravastatin; Prospective Studies; Quinolines; Recovery of Function; Republic of Korea; Stroke Volume; Time Factors; Treatment Outcome; Ventricular Function, Left; Ventricular Remodeling | 2014 |
Effect of preoperative oral pravastatin reload in systemic inflammatory response and myocardial damage after coronary artery bypass grafting. A pilot double-blind placebo-controlled study.
Topics: Administration, Oral; Aged; Anti-Inflammatory Agents; Biomarkers; Cardiopulmonary Bypass; Coronary Artery Bypass; Coronary Artery Disease; Creatine Kinase; Double-Blind Method; Drug Administration Schedule; Dyslipidemias; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Nitric Oxide; Nitric Oxide Synthase Type II; Pilot Projects; Pravastatin; Preoperative Care; Risk Factors; Spain; Systemic Inflammatory Response Syndrome; Time Factors; Treatment Outcome | 2015 |
Improvement in Renal Function and Reduction in Serum Uric Acid with Intensive Statin Therapy in Older Patients: A Post Hoc Analysis of the SAGE Trial.
Topics: Aged; Aged, 80 and over; Atorvastatin; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Dyslipidemias; Female; Glomerular Filtration Rate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Male; Pravastatin; Renal Insufficiency, Chronic; Uric Acid | 2015 |
Pitavastatin 4 mg Provides Significantly Greater Reduction in Remnant Lipoprotein Cholesterol Compared With Pravastatin 40 mg: Results from the Short-term Phase IV PREVAIL US Trial in Patients With Primary Hyperlipidemia or Mixed Dyslipidemia.
Topics: Aged; Cholesterol; Cholesterol, LDL; Double-Blind Method; Dyslipidemias; Female; Humans; Hyperlipidemias; Lipids; Lipoproteins; Male; Middle Aged; Pravastatin; Quinolines | 2016 |
Greater remnant lipoprotein cholesterol reduction with pitavastatin compared with pravastatin in HIV-infected patients.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Cholesterol; Double-Blind Method; Dyslipidemias; Female; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins; Male; Middle Aged; Pravastatin; Quinolines; Treatment Outcome; Ultracentrifugation; Young Adult | 2017 |
Comparison of the effect of lipophilic and hydrophilic statins on serum adiponectin levels in patients with mild hypertension and dyslipidemia: Kinki Adiponectin Interventional (KAI) Study.
Topics: Adiponectin; Adipose Tissue; Adult; Aged; Aged, 80 and over; C-Reactive Protein; Cholesterol; Dyslipidemias; Female; Humans; Hydrophobic and Hydrophilic Interactions; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Pravastatin; Prospective Studies; Simvastatin | 2008 |
Pravastatin for cardiovascular event primary prevention in patients with mild-to-moderate hypertension in the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study.
Topics: Aged; Anticholesteremic Agents; Blood Pressure; Cardiovascular Diseases; Cerebral Infarction; Cholesterol; Combined Modality Therapy; Coronary Disease; Diet; Dyslipidemias; Female; Follow-Up Studies; Humans; Hypertension; Incidence; Japan; Male; Middle Aged; Pravastatin; Severity of Illness Index | 2009 |
Rosuvastatin versus pravastatin in dyslipidemic HIV-1-infected patients receiving protease inhibitors: a randomized trial.
Topics: Adult; Anticholesteremic Agents; Cholesterol, LDL; Dyslipidemias; Female; Fluorobenzenes; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Pravastatin; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Viral Load | 2010 |
Efficacy and safety of ezetimibe for Japanese patients with dyslipidaemia: The ESSENTIAL Study.
Topics: Aged; Anticholesteremic Agents; Asian People; Azetidines; Cholesterol; Clinical Chemistry Tests; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medication Adherence; Metabolic Syndrome; Middle Aged; Pravastatin; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Triglycerides | 2010 |
Blood pressure control status and effects of pravastatin on cardiovascular events occurrence in patients with dyslipidaemia.
Topics: Adult; Aged; Blood Pressure; Cerebrovascular Disorders; Dyslipidemias; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Male; Middle Aged; Pravastatin; Proportional Hazards Models; Prospective Studies | 2012 |
Effect of dalcetrapib plus pravastatin on lipoprotein metabolism and high-density lipoprotein composition and function in dyslipidemic patients: results of a phase IIb dose-ranging study.
Topics: Adolescent; Adult; Aged; Amides; Anticholesteremic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Electrophoresis, Polyacrylamide Gel; Esters; Female; Follow-Up Studies; Humans; Lipoproteins, HDL; Magnetic Resonance Spectroscopy; Male; Middle Aged; Pravastatin; Sulfhydryl Compounds; Treatment Outcome; Young Adult | 2012 |
Pitavastatin shows greater lipid-lowering efficacy over 12 weeks than pravastatin in elderly patients with primary hypercholesterolaemia or combined (mixed) dyslipidaemia.
Topics: Aged; Aged, 80 and over; Cholesterol, LDL; Double-Blind Method; Drug Tolerance; Dyslipidemias; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Pravastatin; Quinolines; Time Factors; Treatment Outcome | 2013 |
Impacts of estimated glomerular filtration rate on coronary atherosclerosis and plaque composition before and during statin therapy in patients with normal to mild renal dysfunction: subanalysis of the TRUTH study.
Topics: Aged; Biomarkers; Coronary Artery Disease; Coronary Vessels; Dyslipidemias; Female; Fibrosis; Glomerular Filtration Rate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Kidney; Kidney Diseases; Lipids; Male; Middle Aged; Multivariate Analysis; Percutaneous Coronary Intervention; Plaque, Atherosclerotic; Pravastatin; Prospective Studies; Quinolines; Risk Assessment; Risk Factors; Severity of Illness Index; Time Factors; Treatment Outcome; Ultrasonography, Interventional | 2012 |
Effects of rosuvastatin versus pravastatin on low-density lipoprotein diameter in HIV-1-infected patients receiving ritonavir-boosted protease inhibitor.
Topics: Adult; Anticholesteremic Agents; Cholesterol, LDL; Double-Blind Method; Dyslipidemias; Female; Fluorobenzenes; France; HIV Protease Inhibitors; HIV Seropositivity; HIV-1; Humans; Male; Middle Aged; Pravastatin; Pyrimidines; Ritonavir; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2012 |
Effects of pravastatin and atorvastatin on HDL cholesterol and glucose metabolism in patients with dyslipidemia and glucose intolerance: the PRAT study.
Topics: Adult; Atorvastatin; Blood Glucose; Cholesterol, HDL; Dyslipidemias; Female; Glucose; Glucose Intolerance; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Postmenopause; Pravastatin; Pyrroles; Young Adult | 2013 |
[The effect of statins on lipids peroxidation and activities of antioxidants enzymes in patients with dyslipidemia].
Topics: Adult; Aged; Antioxidants; Atorvastatin; Catalase; Dyslipidemias; Erythrocyte Membrane; Female; Glutathione Peroxidase; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Peroxidation; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Superoxide Dismutase; Treatment Outcome | 2006 |
Lipid-modifying and pleiotropic effects of gemfibrozil, simvastatin and pravastatin in patients with dyslipidemia.
Topics: Dyslipidemias; Female; Gemfibrozil; Humans; Hypolipidemic Agents; Lipids; Male; Middle Aged; Pravastatin; Simvastatin; Treatment Outcome | 2006 |
32 other study(ies) available for pravastatin and Dyslipidemia
| Article | Year |
|---|---|
Relationship between Dietary Habits and Control of Lipid Profiles in Patients with Dyslipidemia Using Pravastatin.
Topics: Aged; Cholesterol; Cholesterol, LDL; Diet; Dyslipidemias; Feeding Behavior; Female; Humans; Lipids; Logistic Models; Male; Middle Aged; Odds Ratio; Pravastatin; Republic of Korea; Surveys and Questionnaires; Triglycerides | 2021 |
Factors associated with statin selection among privately insured commercial and Medicare patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Atorvastatin; Cardiovascular Diseases; Cohort Studies; Comorbidity; Drug Interactions; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Insurance, Health; Male; Medicare; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Sex Factors; Simvastatin; Sulfonamides; United States; Young Adult | 2013 |
Risk of incident diabetes among patients treated with statins: population based study.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Odds Ratio; Ontario; Population Surveillance; Pravastatin; Proportional Hazards Models; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2013 |
Comparison of Cost-Effectiveness, Safety, and Efficacy of Rosuvastatin Versus Atorvastatin, Pravastatin, and Simvastatin in Dyslipidemic Diabetic Patients With or Without Metabolic Syndrome.
Topics: Adult; Atorvastatin; Cost-Benefit Analysis; Diabetes Mellitus; Dyslipidemias; Female; Humans; Hypolipidemic Agents; Lipids; Male; Metabolic Syndrome; Middle Aged; Pravastatin; Rosuvastatin Calcium; Simvastatin; Socioeconomic Factors | 2014 |
[The fixed combination of pravastatin and fenofibrate: what can it provide?].
Topics: Atherosclerosis; Cardiovascular Diseases; Drug Combinations; Dyslipidemias; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type V; Hypolipidemic Agents; Pravastatin; Risk Factors | 2014 |
[Efficacy studies].
Topics: Cardiovascular Diseases; Cholesterol, HDL; Drug Combinations; Dyslipidemias; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Hypolipidemic Agents; Lipids; Pravastatin; Risk Factors | 2014 |
[Achievement of therapeutic objectives].
Topics: Atherosclerosis; Cardiovascular Diseases; Drug Administration Schedule; Drug Combinations; Dyslipidemias; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Medication Adherence; Pravastatin; Risk Factors | 2014 |
[Indications for the combination of pravastatin and fenofibrate according to the type of dyslipidemia].
Topics: Cardiovascular Diseases; Drug Combinations; Dyslipidemias; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipids; Pravastatin; Risk Factors | 2014 |
[Indications for the combination of pravastatin and fenofibrate according to the cardiovascular risk level. Common clinical situations].
Topics: Cardiovascular Diseases; Drug Therapy, Combination; Dyslipidemias; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipids; Pravastatin; Risk Factors | 2014 |
[Treatment of older patients with dyslipidemia].
Topics: Age Factors; Aged; Atherosclerosis; Dyslipidemias; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Practice Guidelines as Topic; Pravastatin; Quality of Life | 2014 |
Appropriate candidates for statin use in heart failure.
Topics: Cholesterol, LDL; Dyslipidemias; Female; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Ischemia; Pravastatin; Quinolines | 2014 |
[Erythrocyte aggregation in patients with arterial hypertension and dyslipidemia treated with pravastatin].
Topics: Anticholesteremic Agents; Antihypertensive Agents; Biological Availability; Drug Monitoring; Dyslipidemias; Enalapril; Erythrocyte Aggregation; Erythrocyte Membrane; Erythrocytes; Female; Humans; Hypertension; Lipid Peroxidation; Male; Middle Aged; Pravastatin; Severity of Illness Index; Treatment Outcome | 2014 |
A population-based analysis of the risk of drug interaction between clarithromycin and statins for hospitalisation or death.
Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Clarithromycin; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Dyslipidemias; Female; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin; Retrospective Studies; Risk; Rosuvastatin Calcium; Simvastatin | 2015 |
Pitavastatin versus Pravastatin in Reduction of Remnant Lipoprotein Cholesterol in Patients with Dyslipidemias.
Topics: Atherosclerosis; Cholesterol; Dyslipidemias; Humans; Pravastatin; Triglycerides | 2016 |
Effect of vildagliptin and pravastatin combination on cholesterol efflux in adipocytes.
Topics: 3T3-L1 Cells; Adamantane; Adipocytes; Animals; ATP Binding Cassette Transporter 1; ATP Binding Cassette Transporter, Subfamily G, Member 1; Cholesterol; Cholesterol, HDL; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Liver X Receptors; Mice; Nitriles; Pravastatin; Pyrrolidines; Vildagliptin | 2016 |
Lipid management: considerations in acute coronary syndrome.
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Pyrroles; Risk Assessment; Risk Factors; Triglycerides | 2008 |
The efficacy and safety of ezetimibe for treatment of dyslipidemia after heart transplantation.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Drug Therapy, Combination; Drug Tolerance; Dyslipidemias; Ezetimibe; Female; Heart Transplantation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Lipids; Male; Middle Aged; Postoperative Complications; Pravastatin; Pyrroles; Young Adult | 2008 |
Safety and efficacy of statin therapy in patients switched from cyclosporine a to sirolimus after cardiac transplantation.
Topics: Adrenal Cortex Hormones; Aged; Atorvastatin; Cholesterol; Cyclosporine; Dyslipidemias; Female; Heart Transplantation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Male; Middle Aged; Postoperative Complications; Pravastatin; Pyrroles; Safety; Sirolimus; Treatment Outcome; Triglycerides | 2008 |
Rhabdomyolysis in an HIV-infected patient on anti-retroviral therapy precipitated by high-dose pravastatin.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Deoxycytidine; Dyslipidemias; Emtricitabine; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Oligopeptides; Organophosphonates; Pravastatin; Pyridines; Rhabdomyolysis; Ritonavir; Tenofovir | 2009 |
Combination treatment to prevent atherosclerosis.
Topics: Anticholesteremic Agents; Antihypertensive Agents; Atherosclerosis; Blood Pressure; Drug Therapy, Combination; Dyslipidemias; Humans; Hypertension; Pravastatin | 2009 |
HIV-associated dyslipidaemia among HIV antibody-positive patients in Ireland: prevalence and management strategies.
Topics: Anti-HIV Agents; Anticholesteremic Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Dyslipidemias; Gemfibrozil; HIV Infections; HIV Protease Inhibitors; Humans; Hypolipidemic Agents; Ireland; Pravastatin; Prevalence; Retrospective Studies | 2010 |
Pravastatin potentiates increases in serum adiponectin concentration in dyslipidemic patients receiving thiazolidinedione: the DOLPHIN study.
Topics: Adiponectin; Anticholesteremic Agents; Drug Synergism; Dyslipidemias; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin; Thiazolidinediones | 2010 |
High-sensitivity C-reactive protein levels fall during statin therapy in HIV-infected patients receiving ritonavir-boosted protease inhibitors.
Topics: Anticholesteremic Agents; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Dyslipidemias; Female; HIV Infections; Humans; Male; Middle Aged; Pravastatin; Ritonavir | 2011 |
Low-density lipoprotein cholesterol goal attainment among Malaysian dyslipidemic patients.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Logistic Models; Malaysia; Male; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2011 |
High-sensitivity C-reactive protein levels do not decrease with the use of statins in all persons with HIV infection.
Topics: C-Reactive Protein; Cardiovascular Diseases; Dyslipidemias; Female; HIV Infections; Humans; Male; Pravastatin; Ritonavir | 2011 |
Adherence to preferable behavior for lipid control by high-risk dyslipidemic Japanese patients under pravastatin treatment: the APPROACH-J study.
Topics: Aged; Asian People; Awareness; Coronary Artery Disease; Diet; Dyslipidemias; Exercise; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Patient Compliance; Pravastatin; Primary Prevention; Prognosis; Surveys and Questionnaires | 2012 |
Risk reductions for cardiovascular disease with pravastatin treatment by dyslipidemia phenotype: a post hoc analysis of the MEGA Study.
Topics: Adult; Aged; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, HDL; Dyslipidemias; Electrophoresis; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Phenotype; Pravastatin; Randomized Controlled Trials as Topic; Regression Analysis; Risk Reduction Behavior; Time Factors | 2013 |
Inhibition of cholesterol synthesis causes both hypercholesterolemia and hypocholesterolemia in hamsters.
Topics: Animals; Anticholesteremic Agents; Benzylamines; Cholesterol, HDL; Cricetinae; Dose-Response Relationship, Drug; Dyslipidemias; Enzyme Inhibitors; Male; Mesocricetus; Pravastatin | 2002 |
Differential associations of statin and fibrate treatment with carotid arterial remodeling.
Topics: Adult; Atorvastatin; Bezafibrate; Body Mass Index; Carotid Arteries; Cholesterol, HDL; Clofibric Acid; Cohort Studies; Dyslipidemias; Fatty Acids, Monounsaturated; Female; Fenofibrate; Fibric Acids; Fluvastatin; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Male; Middle Aged; Multivariate Analysis; Pravastatin; Pyridines; Pyrroles; Risk Factors; Simvastatin; Treatment Outcome; Tunica Intima; Tunica Media; Ultrasonography | 2005 |
Pravastatin improves insulin resistance in dyslipidemic patients.
Topics: Aged; Anticholesteremic Agents; Carotid Arteries; Dyslipidemias; Female; Glucose; Humans; Insulin Resistance; Male; Middle Aged; Pravastatin; Ultrasonography | 2005 |
Multitherapy for diabetes.
Topics: Bezafibrate; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyslipidemias; Humans; Hypolipidemic Agents; Pravastatin | 2006 |
Safety of lovastatin/extended release niacin compared with lovastatin alone, atorvastatin alone, pravastatin alone, and simvastatin alone (from the United States Food and Drug Administration adverse event reporting system).
Topics: Adverse Drug Reaction Reporting Systems; Atorvastatin; Chemical and Drug Induced Liver Injury; Drug Prescriptions; Drug Therapy, Combination; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Liver Diseases; Lovastatin; Niacin; Pravastatin; Prevalence; Pyrroles; Retrospective Studies; Rhabdomyolysis; Risk Factors; Simvastatin; United States; United States Food and Drug Administration | 2007 |